However, since the approval of afatinib for use in patients with uncommon EGFR mutations by the US Food and Drug Administration in 2018, the landscape may have changed regarding survival outcomes and the clinical significance of this mutation for Taiwanese patients with NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.